August holds 5 big FDA decisions; Spark weighs installment payments for blindness therapy;

> The FDA this month is expected to announce big approval decisions for companies including Bristol-Myers Squibb ($BMY), Alkermes ($ALKS) and Amgen ($AMGN). Report

> In Q2, Endo's ($ENDP) branded pharma revenue increased 27%, while generics posted a 24% top-line rise. Release

> Spark Therapeutics ($ONCE) is weighing installment payments for a gene therapy candidate for blindness that analysts predict will be pricey. Report

> Kwang Dong Pharma will market Orexigen's ($OREX) weight loss drug, Contrave, in South Korea. Report

> Shire ($SHPG) has launched the second annual Excellence in ADHD Patient Group Awards. Release

> People on extended-interval prophylaxis regimens with new, long-acting Biogen ($BIIB) hemophilia therapy Eloctate experienced low bleeding rates in a Phase III study. Release

> GlaxoSmithKline ($GSK) is rolling out a tooth sensitivity awareness campaign for Sensodyne toothpaste in India. Report

And Finally... A U.K. company is preparing to launch the first traditional Chinese medicine approved in the country. Report (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.